Search PubMed⌕ Search

Biomedical subjects

M V Pimm

Publications and source records attributed to M V Pimm.

At least 145 records · Page 8Linked to original sources
PubMed1975

BCG therapy of pleural and peritoneal growth of transplanted rat tumours.

Growth of intrapleurally injected cells of immunogenic methylcholanthrene-induced rat sarcomas was suppressed by intrapleural injection of viable or 1 times 10-6 R radiation-sterilized BCG vaccine. As little as 10 mug moist weight of organisms was effective, and treatment could be given several days before or after tumour challenge. Pleural effusion growth of a moderately immunogenic ascitic hepatoma was also controlled by intrapleurally administered BCG. In contrast, BCG injected intravenously, subcutaneously or intraperitoneally was without influence on pleural tumour growths. Similarly, intraperitoneal growth of these tumours was suppressed only by intraperitoneal injection of BCG. With two other transplanted tumours, a chemically induced mammary carcinoma and a spontaneous sarcoma, both of which lack significant immunogenicity, BCG treatment of pleural and peritoneal growths was less successful and more variable. Nevertheless, these studies indicate the potential of this type of treatment of thoracic and peritoneal tumour deposits for possible clinical application in the treatment of malignant mesothelioma.

Animals↗
PubMed1975

Methanol extraction residue of BCG in the treatment of transplanted rat tumours.

Subcutaneous growth of immunogenic chemically induced rat sarcomata and a hepatoma was restricted when cells were injected into syngeneic animals in admixture with MER. Rats rejecting mixed inocula were immune to further challenge with the same tumour. Growth of a chemically induced mammary carcinoma which lacks detectable immunogenicity was suppressed when low cell inocula were injected in admixture with MER or intact BCG organisms, although animals were not immune to re-challenge. These studies indicate that clinically MER may be a suitable alternative to BCG for contact suppression of tumour growth or incorporation into tumour cell:adjuvant vaccines for active immunotherapy.

Animals↗
PubMed1975

Levamisole treatment of local and metastatic growth of transplanted rat tumours.

Levamisole has been examined for its ability to control local growth and pulmonary metastases of transplanted rat tumours. The compound did not suppress subcutaneous growth of 3-methylcholanthrene induced sarcomata when administered systemically in a variety of regimens, or when injected in admixture with tumour cells. In addition, levamisole treatment failed to suppress pulmonary growth of intravenously transferred sarcoma cells or spontaneous pulmonary metastases appearing after surgical removal of a transplanted epithelioma.

Animals↗
PubMed1975

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.

ICRF 159 and Triton WR 1339 have been examined for their ability to suppress subcutaneous growth and pulmonary metastases from a transplanted rat epithelioma. Neither compound influenced subcutaneous tumour development or reduced the propensity to metastasize when administered in regimens reported to suppress pulmonary, lymph node or intracerebral metastases in other experimental system.

Animals↗
PubMed1973

BCG immunotherapy of a rat sarcoma.

Growth of syngeneic transplants of a 3-methylcholanthrene induced rat sarcoma was suppressed when tumour cells were injected in admixture with BCG. Rejection of these mixed inocula resulted in the suppression of growth of a simultaneous challenge with cells of the same tumour at a contralateral subcutaneous site and conditions for immunotherapy were evaluated with respect to the maximum tumour cell challenge rejected and the optimum time of treatment. These studies established that viable tumour cells were more effective than radiation attenuated cells for the immunizing stimulus. Also, the maximum tumour challenge totally rejected in this way was of the order of 10(6) cells, and with this rapidly growing tumour, treatment had to be initiated within 4 days of tumour injection. These observations are relevant to current proposals for adjuvant immunotherapy of human malignant disease where conditions of minimal residual disease are not being fulfilled.

Animals↗
PubMed1973

BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells.

Pulmonary growths produced by intravenous injection of methycholanthrene-induced sarcoma cells were controlled or suppressed by specific immunostimulation with BCG-sarcoma cell inocula at subcutaneous sites or by intravenous treatment with BCG alone. The response was dependent upon the immunogenicity of the treated tumour so that in comparison, intravenous injection of BCG enhanced rather than suppressed pulmonary growths of transferred cells of several weakly immunogenic tumours including a spontaneously arising sarcoma and an epithelioma as well as a carcinogen-induced mammary carcinoma.

Adjuvants, Immunologic↗